|
|
 |
|
OPTR: Optimer Pharmaceuticals Inc - Stock News |
Enter Ticker:
|
|
| Nov 12, 2009 |
OPTR: Completes Enrollment for Phase 3 Trial of Fidaxomicin for CDI |
| Nov 12, 2009 |
Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection |
| Nov 04, 2009 |
Analyst Downgrades for November 4th |
| Nov 03, 2009 |
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results |
| Oct 31, 2009 |
Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting |
| Oct 26, 2009 |
Optimer Pharmaceuticals to Present at November 2009 Investor Conferences |
| Oct 19, 2009 |
Optimer Pharmaceuticals Announces Presentations of Additional Data From the Fidaxomicin North American Phase 3 Trial at Upcoming IDSA Annual Meeting |
| Oct 15, 2009 |
BUYINS.NET: Short Sale Recap. Highest % Of Daily Trading Volume Short All Exchanges Combined For Wednesday |
| Sep 30, 2009 |
BUYINS.NET: Short Sale Recap. Highest % Of Daily Trading Volume Short All Exchanges Combined For Tuesday |
| Sep 29, 2009 |
BUYINS.NET: Short Sale Recap. Highest % Of Daily Trading Volume Short All Exchanges Combined For Monday |
| Sep 28, 2009 |
Optimer Pharmaceuticals to Present at October 2009 Investor Conferences |
| Sep 15, 2009 |
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) |
| Sep 15, 2009 |
BiomedReports: News and FDA Updates for Optimer (Nasdaq:OPTR), Emergent BioSolutions (NYSE:EBS), Elan (NYSE:ELN), Sucampo (NASDAQ:SCMP) |
| Sep 14, 2009 |
Data From Optimer's Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) |
| Sep 09, 2009 |
StockPreacher.com Issues Trading Outlook for Genova Biotherapeutics Inc. |
| |
| ZACKS COMMENTARY FOR OPTR |
|
|
|
Sponsored Links 
-0.11